Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study

NCT07696832 is registered in ClinicalTrials.gov with Guangdong Association of Clinical Trials as lead sponsor.

NCT NCT07696832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07696832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
Lead sponsor
Guangdong Association of Clinical Trials
Phase
Observational
Overall status
Recruiting
Start date
January 20, 2026
Completion date
June 30, 2027
Enrollment
265 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

eastern cooperative oncology group performance status (ecog ps) score of 0 to 2, egfr mutation-negative and alk rearrangement-negative, no prior systemic therapy received for the advanced or metastatic disease, patients must have histologically or cytologically confirmed locally advanced or metastatic nsclc, pd-l1 positive, as determined by a validated assay